$GTM

GTM Investment Deadline: ZoomInfo Securities Fraud Class Action Focuses on AI Integration Issues; Investors Notified of August 24 Court Deadline

Bleichmar Fonti & Auld LLP said a securities fraud class action was filed against ZoomInfo Technologies (NASDAQ:GTM) and executives after the stock fell about 33% in May 2026. The suit alleges ZoomInfo misled investors about how its AI products affected customer retention and cut 2026 revenue guidance to $1.185–$1.205B. Investors can seek lead-plaintiff status by Aug. 24, 2026.

Original reporting
Published Jul 7, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 11:19 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GTM Investment Deadline: ZoomInfo Securities Fraud Class Action Focuses on AI Integration Issues; Investors Notified of August 24 Court Deadline — source image
Decision brief

The 30-second read

$GTMBearishMed
01

Why it matters

The key tradable element is the newly disclosed legal timeline (lead plaintiff deadline) and the specific allegation linkage to AI product messaging and customer retention deterioration after the May 2026 guidance cut.

02

Market read

A new lawsuit renews securities-fraud risk for ZoomInfo and can drive volatility ahead of the Aug 24, 2026 lead-plaintiff appointment deadline.

03

What to watch

Traders may want to monitor whether ZoomInfo issues any supplemental disclosures, settlement discussions, or motions to dismiss that could change perceived litigation risk.

Relevance 7/10Novelty 6/10Timing: Lead plaintiff deadline: August 24, 2026

Background

The article describes a securities fraud class action filed in the Western District of Washington, alleging ZoomInfo misled investors about AI-integrated product effects on customer retention.

Company-level read

Ticker impact

$GTMBearishMedium confidence
Context

ZoomInfo (GTM) is named as the defendant in a newly filed securities fraud class action tied to alleged AI-driven customer retention issues.

Expected impact

Near-term sentiment pressure is likely, with potential volatility around legal developments and any related disclosures.

Evidence & confidence

The article is a fresh filing with a defined lead-plaintiff deadline (Aug 24, 2026) and ties allegations to previously disclosed guidance/regression language, which can renew investor risk concerns even without new financial results.

Market effects

Highlights litigation risk for GTM/CRM and AI-enabled sales/marketing software vendors when retention metrics are questioned.

Primarily US-focused legal/regulatory overhang; could affect sentiment for other US-listed SaaS names with AI product narratives.

Limited direct global impact, but reinforces broader investor scrutiny of AI-driven go-to-market claims.

Counterpoint

A filed complaint is not a finding of wrongdoing; the market may already be pricing the underlying guidance/retention narrative from the May 2026 move.

Key entities

  • ZoomInfo Technologies Inc.

    Defendant in a newly filed securities fraud class action alleging misleading statements about AI-driven customer retention.

  • Tejeda v. ZoomInfo Technologies et al., No. 26-cv-05696

    Case caption and docket number cited as pending in the U.S. District Court for the Western District of Washington.

  • U.S. District Court for the Western District of Washington

    Venue where the class action is pending.

Related articles

$GTMMed

GTM Q2 Deep Dive: Upmarket Focus and Hybrid Pricing Strategy Take Center Stage

ZoomInfo (NASDAQ:GTM) reported Q2 CY2026 revenue of $310.4 million, up 1.2% year over year, beating expectations. Midpoint Q3 revenue guidance was $299.5 million, 1.6% above estimates. Non-GAAP EPS was $0.28, 5.8% above consensus. Management cited upmarket growth, 20% growth in its operations/data business, and a transition to hybrid consumption-based pricing plus AI products like GTM.AI.

$GTMMed

Year Outlook Slightly Exceeds Expectations

ZoomInfo (NASDAQ: GTM) reported Q2 CY2026 revenue of $310.4 million, up 1.2% year on year, beating Wall Street expectations. Next-quarter revenue guidance had a $299.5 million midpoint, 1.6% above estimates. Non-GAAP EPS was $0.28, 5.8% above consensus. The article also cites billings of $295.8 million and 1,891 enterprise customers.

$GTMHigh

ZoomInfo Technologies Inc. (GTM): Results of Operations and Financial Condition

ZoomInfo Technologies Inc. (GTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gtm-8kex991x20260805.htm EX-99.1 Document Exhibit 99.1 ZoomInfo Announces Second Quarter 2026 Financial Results VANCOUVER, Wash. , August 5, 2026 - ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, today announced its financial results for the second quarter ended

$GTMMedAI 8/10

ZoomInfo (GTM) Launches Native App Inside OpenAI Codex for Work

ZoomInfo said OpenAI made ZoomInfo natively available inside OpenAI Codex for Work, a B2B data and go-to-market intelligence app. ZoomInfo stated OpenAI selected it to bring verified company intelligence, contacts, and go-to-market signals into Codex so users can run its skills via natural language. Separately, analysts at Morgan Stanley and JPMorgan cut price targets after lower free cash flow and fiscal 2026 outlook.

$GTMMedAI 9/10

Is ZoomInfo Technologies Inc. (GTM) One of the Best Tech Stocks Under $5 to Buy?

Jefferies downgraded ZoomInfo (GTM) to Hold from Buy on May 21, cutting its price target to $4 from $12 and citing a “material” reduction in projected 2026 revenue growth plus no improvement expected in 2027. The firm said client demand has been weak for two years and AI is changing purchasing behavior. Morgan Stanley on May 19 cut its target to $5 from $9, keeping Equal Weight.

$AMGNMed

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen (AMGN) shares rose about 6.7% after the EMA CHMP issued a positive opinion to expand Repatha’s use in Europe for adults with or at high risk for atherosclerotic cardiovascular disease, based on Phase 3 VESALIUS-CV results. If approved by the European Commission, it could widen the eligible patient pool. The article cites Q2 2026 revenue of $10,054 million and net income of $2,375 million.